News | January 29, 2015

Medtronic Study Finds Corevalve System Benefits Aortic Stenosis Patients with Prior Coronary Bypass Surgery

Analysis is first to show significant advantages for transcatheter aortic valve in patients with prior CABG

Clinical trial/Study, Heart Valve Repair, CoreValve System

Image courtesy of Medtronic

January 29, 2015 — Medtronic revealed new one-year clinical data showing that transcatheter aortic valve replacement (TAVR) with the self-expanding CoreValve System offers advantages in survival and safety compared to surgical aortic valve replacement (SAVR) in high risk aortic stenosis patients who have previously undergone coronary artery bypass grafting (CABG) surgery. This is the first analysis to evaluate a self-expanding valve in prior-CABG patients within a trial of TAVR and SAVR.

Presented at the 2015 Annual Meeting of The Society of Thoracic Surgeons (STS), the post-hoc sub-analysis of the High Risk Study of the CoreValve U.S. Pivotal Trial included 226 prior-CABG patients who were either treated with TAVR (N=115) or SAVR (N=111).

At one year, there was a significant difference favoring TAVR with CoreValve in the combined primary study endpoint of all-cause mortality or major stroke with an incidence of 11.4 percent in the TAVR group versus 21.8 percent in the SAVR group (p=0.04).  Additionally, there was a trend towards a survival advantage for patients who received TAVR with CoreValve compared to SAVR (90.4 percent versus 81.9 percent, respectively; p=0.06) and lower rates of cardiovascular mortality (7.0 percent versus 13.8 percent, respectively; p=0.10).

“Prior to now, the treatment of this patient population has been confounded by the lack of data showing clinical benefit of TAVR versus surgical aortic valve replacement for prior-CABG aortic stenosis patients, who may have increased risks of mortality and morbidity with re-operation.,” said John Conte, M.D., professor of surgery at The Johns Hopkins Hospital who presented the data at STS. “The CoreValve System demonstrated important clinical advantages including faster recovery compared to surgical valve replacement offering heart teams an alternative to open heart surgery for this patient population.”

The analysis also showed reduced complications for patients receiving TAVR versus SAVR at one year, including lower rates of acute kidney injury (5.3 percent versus 16.3 percent; p=0.007), life threatening or disabling bleeding (14.0 percent versus 43.5 percent; p<0.001), as well as lower MACCE with the TAVR-treated patients (17.5 percent versus 28.1 percent, respectively; p=0.05). There was no difference in the overall rates of all stroke (10.6 percent versus 14.3 percent, p=<0.40) or major stroke (8.8 percent versus 6.6 percent; p=<0.54) between the two patient groups

The CoreValve System is available for use in the United States, following U.S. Food and Drug Administration (FDA) approval in 2014 for patients at extreme risk and high risk for surgery. Since receiving CE Mark in 2007, the CoreValve System has been implanted in more than 70,000 patients in more than 60 countries.

For more information:



Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init